PXMD (PaxMedica) Net Margin %: 0.00% (As of Sep. 2024)


What is PaxMedica Net Margin %?

PaxMedica PXMD Net Margin % is 0.00% as of Sep. 2024.

Net margin is calculated as Net Income divided by its Revenue. PaxMedica's Net Income for the three months ended in Sep. 2024 was $-0.88 Mil. PaxMedica's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, PaxMedica's net margin for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for PaxMedica's Net Margin % or its related term are showing as below:


PXMD's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

PaxMedica  (OTCPK:PXMD) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

PaxMedica Net Margin % Related Terms

PaxMedica Net Margin % Historical Data

* Premium members only.

The historical data trend for PaxMedica's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PaxMedica Net Margin % Chart

PaxMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

PaxMedica Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PXMD vs BTAX, NBIO, ARTHQ: Net Margin % Comparison

For the Biotechnology subindustry, PaxMedica's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PaxMedica Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PaxMedica's Net Margin % distribution charts can be found below:

* The bar in red indicates where PaxMedica's Net Margin % falls into.


PaxMedica Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

PaxMedica's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-18.29/0
= %

PaxMedica's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-0.877/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
PaxMedica (PXMD) has a Net Margin % of 0.00% as of Sep. 2024. Net margin is the ratio of total net income to net sales. View historical data on PaxMedica and its competitors.
Is PaxMedica's Net Margin % too high?
PaxMedica's current Net Margin % is 0.00%.
How does PaxMedica's Net Margin % compare to BTAX and NBIO?
PaxMedica's Net Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on PaxMedica and its competitors. PaxMedica's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PaxMedica stock overvalued right now?
PaxMedica (PXMD) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For PaxMedica (PXMD), the current Net Margin % is 0.00% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PaxMedica Business Description

Address 303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.